Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 579

1.

FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.

Crawford ED, Tombal B, Keane T, Boccardo F, Miller K, Shore N, Moul JW, Damber JE, Collette L, Persson BE.

Scand J Urol. 2019 Jan 9:1-9. doi: 10.1080/21681805.2018.1522372. [Epub ahead of print]

PMID:
30624128
2.

Detection of Cryptococcus DNA by metagenomic next-generation sequencing in symptomatic cryptococcal antigenemia.

Ramachandran PS, Cresswell FV, Meya DB, Crawford ED, DeRisi JL, Boulware DR, Wilson MR.

Clin Infect Dis. 2018 Dec 8. doi: 10.1093/cid/ciy1024. [Epub ahead of print] No abstract available.

PMID:
30535266
3.

Integrating host response and unbiased microbe detection for lower respiratory tract infection diagnosis in critically ill adults.

Langelier C, Kalantar KL, Moazed F, Wilson MR, Crawford ED, Deiss T, Belzer A, Bolourchi S, Caldera S, Fung M, Jauregui A, Malcolm K, Lyden A, Khan L, Vessel K, Quan J, Zinter M, Chiu CY, Chow ED, Wilson J, Miller S, Matthay MA, Pollard KS, Christenson S, Calfee CS, DeRisi JL.

Proc Natl Acad Sci U S A. 2018 Dec 26;115(52):E12353-E12362. doi: 10.1073/pnas.1809700115. Epub 2018 Nov 27.

4.

Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer.

Kessler ER, Su LJ, Gao D, Torkko KC, Wacker M, Anduha M, Chronister N, Maroni P, Crawford ED, Flaig TW, Glode LM, Lam ET.

Integr Cancer Ther. 2018 Dec;17(4):1103-1108. doi: 10.1177/1534735418803755. Epub 2018 Oct 5.

5.

Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial.

Pinsky PF, Miller E, Prorok P, Grubb R, Crawford ED, Andriole G.

BJU Int. 2018 Oct 5. doi: 10.1111/bju.14580. [Epub ahead of print]

PMID:
30288918
6.

Pulmonary Metagenomic Sequencing Suggests Missed Infections in Immunocompromised Children.

Zinter MS, Dvorak CC, Mayday MY, Iwanaga K, Ly NP, McGarry ME, Church GD, Faricy LE, Rowan CM, Hume JR, Steiner ME, Crawford ED, Langelier C, Kalantar K, Chow ED, Miller S, Shimano K, Melton A, Yanik GA, Sapru A, DeRisi JL.

Clin Infect Dis. 2018 Sep 15. doi: 10.1093/cid/ciy802. [Epub ahead of print]

PMID:
30239621
7.

Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations.

Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, Miller K, Debruyne FMJ, Klotz L.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):24-38. doi: 10.1038/s41391-018-0079-0. Epub 2018 Aug 21.

8.

A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III).

Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, Gomella LG, Karsh L, Keane TE, Maroni P, Penson D, Petrylak DP, Ross A, Mouraviev V, Reiter RE, Divgi C, Yu EY; RADAR III Group.

J Urol. 2019 Jan 18. doi: 10.1016/j.juro.2018.05.164. [Epub ahead of print]

PMID:
30077557
9.

Transrectal Ultrasound-guided Versus Transperineal Mapping Prostate Biopsy: Complication Comparison.

Skouteris VM, Crawford ED, Mouraviev V, Arangua P, Metsinis MP, Skouteris M, Zacharopoulos G, Stone NN.

Rev Urol. 2018;20(1):19-25. doi: 10.3909/riu0785.

10.

Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.

Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F.

J Urol. 2018 Nov;200(5):956-966. doi: 10.1016/j.juro.2018.04.083. Epub 2018 May 3. Review.

PMID:
29730201
11.

Editorial Comment.

Crawford ED.

J Urol. 2018 Aug;200(2):343. doi: 10.1016/j.juro.2018.03.136. Epub 2018 Apr 19. No abstract available.

PMID:
29679579
12.

Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance.

Lin DW, Crawford ED, Keane T, Evans B, Reid J, Rajamani S, Brown K, Gutin A, Tward J, Scardino P, Brawer M, Stone S, Cuzick J.

Urol Oncol. 2018 Jun;36(6):310.e7-310.e13. doi: 10.1016/j.urolonc.2018.03.011. Epub 2018 Apr 11.

PMID:
29655620
13.

The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer.

Ryan CJ, Crawford ED, Shore ND, Underwood W 3rd, Taplin ME, Londhe A, Francis PSJ, Phillips J, McGowan T, Kantoff PW.

J Urol. 2018 Aug;200(2):344-352. doi: 10.1016/j.juro.2018.03.125. Epub 2018 Apr 6.

PMID:
29630978
14.

Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.

Hussain M, Tangen CM, Thompson IM Jr, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM.

J Clin Oncol. 2018 May 20;36(15):1498-1504. doi: 10.1200/JCO.2017.76.4126. Epub 2018 Apr 6.

PMID:
29624463
15.

The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer.

Maccini MA, Westfall NJ, Van Bokhoven A, Lucia MS, Poage W, Maroni PD, Wilson SS, Glodé LM, Arangua P, Newmark J, Steiner M, Werahera PN, Crawford ED.

Prostate. 2018 May;78(7):506-511. doi: 10.1002/pros.23495. Epub 2018 Feb 19.

PMID:
29460452
16.

Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects.

Saltzstein D, Shore ND, Moul JW, Chu F, Concepcion R, de la Motte S, McLane JA, Atkinson S, Yang A, Crawford ED.

Ther Adv Urol. 2017 Nov 22;10(2):43-50. doi: 10.1177/1756287217738150. eCollection 2018 Feb.

17.

The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.

de Koning HJ, Gulati R, Moss SM, Hugosson J, Pinsky PF, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, de Carvalho TM, Feuer EJ, Tsodikov A, Mariotto AB, Heijnsdijk EAM, Etzioni R.

Cancer. 2018 Mar 15;124(6):1197-1206. doi: 10.1002/cncr.31178. Epub 2017 Dec 6.

PMID:
29211316
18.

Fewer Recurrences with Immediate versus Delayed Intravesical Mitomycin C: A Prospective Randomized European Trial.

Wilson SS, Crawford ED.

Eur Urol. 2018 Feb;73(2):233-235. doi: 10.1016/j.eururo.2017.09.014. Epub 2017 Sep 28. No abstract available.

PMID:
28967551
19.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, Feuer EJ, de Koning HJ, Mariotto AB, Etzioni R.

Ann Intern Med. 2017 Oct 3;167(7):449-455. doi: 10.7326/M16-2586. Epub 2017 Sep 5.

20.

Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.

Petrylak DP, Crawford ED.

Target Oncol. 2017 Aug;12(4):401-412. doi: 10.1007/s11523-017-0500-y. Review.

PMID:
28620691
21.

The 3DBiopsy Prostate Biopsy System: Preclinical Investigation of a Needle, Actuator, and Specimen Collection Device Allowing Sampling of Individualized Prostate Lengths Between 20 and 60 mm.

Stone NN, Mouraviev V, Schechter D, Lucia MS, Smith EE, Arangua P, Hoenemeyer J, Rosa J, Bawa R, Crawford ED.

Urology. 2017 Sep;107:257-261. doi: 10.1016/j.urology.2017.05.046. Epub 2017 Jun 7.

PMID:
28601561
22.

Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas.

Krings G, Joseph NM, Bean GR, Solomon D, Onodera C, Talevich E, Yeh I, Grenert JP, Hosfield E, Crawford ED, Jordan RC, van Zante A, Zaloudek C, Shin SJ, Chen YY.

Mod Pathol. 2017 Aug;30(8):1086-1099. doi: 10.1038/modpathol.2017.32. Epub 2017 May 26.

23.

Plasmid-free CRISPR/Cas9 genome editing in Plasmodium falciparum confirms mutations conferring resistance to the dihydroisoquinolone clinical candidate SJ733.

Crawford ED, Quan J, Horst JA, Ebert D, Wu W, DeRisi JL.

PLoS One. 2017 May 22;12(5):e0178163. doi: 10.1371/journal.pone.0178163. eCollection 2017.

24.

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility.

Crawford ED, Shore ND, Petrylak DP, Higano CS, Ryan CJ.

Ther Adv Med Oncol. 2017 May;9(5):319-333. doi: 10.1177/1758834017698644. Epub 2017 Mar 22. Review.

25.

The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy.

Crawford ED, Schally AV, Pinthus JH, Block NL, Rick FG, Garnick MB, Eckel RH, Keane TE, Shore ND, Dahdal DN, Beveridge TJR, Marshall DC.

Urol Oncol. 2017 May;35(5):183-191. doi: 10.1016/j.urolonc.2017.01.025. Epub 2017 Mar 18. Review.

26.

The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II).

Crawford ED, Petrylak DP, Shore N, Saad F, Slovin SF, Vogelzang NJ, Keane TE, Koo PJ, Gomella LG, O'Sullivan JM, Tombal B, Concepcion RS, Sieber P, Stone NN, Finkelstein SE, Yu EY; Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR II) Group.

Urology. 2017 Jun;104:150-159. doi: 10.1016/j.urology.2016.12.033. Epub 2017 Mar 14. Review.

PMID:
28302580
27.

Navigating the evolving therapeutic landscape in advanced prostate cancer.

Crawford ED, Petrylak D, Sartor O.

Urol Oncol. 2017 May;35S:S1-S13. doi: 10.1016/j.urolonc.2017.01.020. Epub 2017 Mar 7. Review.

PMID:
28283376
28.

Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database.

Amini A, Raben D, Crawford ED, Flaig TW, Kessler ER, Lam ET, Maroni P, Pugh TJ.

Urol Oncol. 2017 Jun;35(6):438-446. doi: 10.1016/j.urolonc.2017.01.013. Epub 2017 Feb 15.

PMID:
28214281
29.

Prostate Cancer Academy 2016: Presentation summaries.

Crawford ED, Albala DM, Wysocki JS, Lepor H, Ross AE, Finkelstein SE, Keane T, Freedland S, Harris R, Shore ND, Ryan CJ.

Rev Urol. 2016;18(4):205-213. doi: 10.3909/riuPCA2016. No abstract available.

30.

Reduced Insulin/IGF-1 Signaling Restores the Dynamic Properties of Key Stress Granule Proteins during Aging.

Lechler MC, Crawford ED, Groh N, Widmaier K, Jung R, Kirstein J, Trinidad JC, Burlingame AL, David DC.

Cell Rep. 2017 Jan 10;18(2):454-467. doi: 10.1016/j.celrep.2016.12.033.

31.

Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.

Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, Crawford ED, Grubb RL, Andriole GL.

Cancer. 2017 Feb 15;123(4):592-599. doi: 10.1002/cncr.30474. Epub 2016 Dec 1.

32.

Erratum to: Illuminating uveitis: metagenomic deep sequencing identifies common and rare pathogens.

Doan T, Wilson MR, Crawford ED, Chow ED, Khan LM, Knopp KA, O'Donovan BD, Xia D, Hacker JK, Stewart JM, Gonzales JA, Acharya NR, DeRisi JL.

Genome Med. 2016 Nov 22;8(1):123. No abstract available.

33.

Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel.

Kim EH, Andriole GL, Crawford ED, Sjoberg DD, Assel M, Vickers AJ, Lilja H.

J Urol. 2017 Apr;197(4):1041-1047. doi: 10.1016/j.juro.2016.10.089. Epub 2016 Nov 1.

34.

Deflection Analysis of Different Needle Designs for Prostate Biopsy and Focal Therapy.

Stone NN, Mouraviev V, Schechter D, Goetz J, Lucia MS, Smith EE, Crawford ED.

Technol Cancer Res Treat. 2017 Oct;16(5):654-661. doi: 10.1177/1533034616671007. Epub 2016 Oct 5.

35.

Acute West Nile Virus Meningoencephalitis Diagnosed Via Metagenomic Deep Sequencing of Cerebrospinal Fluid in a Renal Transplant Patient.

Wilson MR, Zimmermann LL, Crawford ED, Sample HA, Soni PR, Baker AN, Khan LM, DeRisi JL.

Am J Transplant. 2017 Mar;17(3):803-808. doi: 10.1111/ajt.14058. Epub 2016 Oct 21.

36.

Illuminating uveitis: metagenomic deep sequencing identifies common and rare pathogens.

Doan T, Wilson MR, Crawford ED, Chow ED, Khan LM, Knopp KA, O'Donovan BD, Xia D, Hacker JK, Stewart JM, Gonzales JA, Acharya NR, DeRisi JL.

Genome Med. 2016 Aug 25;8(1):90. doi: 10.1186/s13073-016-0344-6. Erratum in: Genome Med. 2016 Nov 22;8(1):123.

37.

An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care.

Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, Pettaway CA, Shore ND, Arangua P, Hoenemeyer J, Leveridge M, Leapman M, Pinto P, Thompson IM Jr, Carroll P, Eastham J, Gomella L, Klein EA.

Urology. 2016 Oct;96:116-120. doi: 10.1016/j.urology.2016.07.001. Epub 2016 Jul 19. No abstract available.

38.

Prostate cancer: Testosterone therapy for hypogonadal men with prostate cancer.

Catarinicchia SP, Crawford ED.

Nat Rev Urol. 2016 Sep;13(9):497-8. doi: 10.1038/nrurol.2016.118. Epub 2016 Jul 19. Review. No abstract available.

PMID:
27431338
39.

The Role of FSH in Prostate Cancer: A Case Report.

Catarinicchia S, Crawford ED.

Urol Case Rep. 2016 Apr 24;7:23-5. doi: 10.1016/j.eucr.2016.03.011. eCollection 2016 Jul.

40.

Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.

Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD, Pugh TJ.

J Clin Oncol. 2016 Aug 20;34(24):2835-42. doi: 10.1200/JCO.2016.67.4788. Epub 2016 Jun 20.

PMID:
27325855
41.

Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation.

Gusev A, Shi H, Kichaev G, Pomerantz M, Li F, Long HW, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Zheng W, Pettaway CA, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, John EM, Murphy AB, Signorello LB, Carpten J, Leske MC, Wu SY, Hennis AJ, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Witte JS, Casey G, Kaggwa S, Cook MB, Stram DO, Blot WJ, Eeles RA, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Southey MC, Fitzgerald LM, Gronberg H, Wiklund F, Aly M, Henderson BE, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokolorczyk D, Kluzniak W, Cannon-Albright L, Teerlink C, Brenner H, Dieffenbach AK, Arndt V, Park JY, Sellers TA, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Spurdle A, Clements JA, Teixeira MR, Pandha H, Michael A, Paulo P, Maia S, Kierzek A; PRACTICAL consortium, Conti DV, Albanes D, Berg C, Berndt SI, Campa D, Crawford ED, Diver WR, Gapstur SM, Gaziano JM, Giovannucci E, Hoover R, Hunter DJ, Johansson M, Kraft P, Le Marchand L, Lindström S, Navarro C, Overvad K, Riboli E, Siddiq A, Stevens VL, Trichopoulos D, Vineis P, Yeager M, Trynka G, Raychaudhuri S, Schumacher FR, Price AL, Freedman ML, Haiman CA, Pasaniuc B.

Nat Commun. 2016 Apr 7;7:10979. doi: 10.1038/ncomms10979.

42.

Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.

Shore ND, Chu F, Moul J, Saltzstein D, Concepcion R, McLane JA, Atkinson S, Yang A, Crawford ED.

BJU Int. 2017 Feb;119(2):239-244. doi: 10.1111/bju.13482. Epub 2016 Apr 16.

43.

Depletion of Abundant Sequences by Hybridization (DASH): using Cas9 to remove unwanted high-abundance species in sequencing libraries and molecular counting applications.

Gu W, Crawford ED, O'Donovan BD, Wilson MR, Chow ED, Retallack H, DeRisi JL.

Genome Biol. 2016 Mar 4;17:41. doi: 10.1186/s13059-016-0904-5.

44.

Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System.

Sutton SS, Crawford ED, Moul JW, Hardin JW, Kruep E.

World J Urol. 2016 Aug;34(8):1107-13. doi: 10.1007/s00345-015-1754-6. Epub 2016 Jan 11.

PMID:
26753559
45.

Human feasibility study of fluorescence spectroscopy guided optical biopsy needle for prostate cancer diagnosis.

Werahera PN, Jasion EA, Liu Y, Daily JW, Arangua P, Jones C, Nash SR, Morrell M, Crawford ED.

Conf Proc IEEE Eng Med Biol Soc. 2015;2015:7358-61. doi: 10.1109/EMBC.2015.7320091.

PMID:
26737991
46.

Diffuse reflectance spectroscopy can differentiate high grade and low grade prostatic carcinoma.

Werahera PN, Jasion EA, Crawford ED, Lucia MS, van Bokhoven A, Sullivan HT, Kim FJ, Maroni PD, Port JD, Daily JW, La Rosa FG.

Conf Proc IEEE Eng Med Biol Soc. 2016 Aug;2016:5148-5151. doi: 10.1109/EMBC.2016.7591886.

PMID:
28325017
47.

Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.

Crawford ED, Petrylak DP, Higano CS, Kibel AS, Kantoff PW, Small EJ, Shore ND, Ferrari A.

Can J Urol. 2015 Dec;22(6):8048-55. Review.

PMID:
26688132
48.

Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer.

Shore ND, Kella N, Moran B, Boczko J, Bianco FJ, Crawford ED, Davis T, Roundy KM, Rushton K, Grier C, Kaldate R, Brawer MK, Gonzalgo ML.

J Urol. 2016 Mar;195(3):612-8. doi: 10.1016/j.juro.2015.09.072. Epub 2015 Sep 25.

PMID:
26403586
49.

Measurement of testosterone: how important is a morning blood draw?

Crawford ED, Poage W, Nyhuis A, Price DA, Dowsett SA, Gelwicks S, Muram D.

Curr Med Res Opin. 2015;31(10):1911-4. doi: 10.1185/03007995.2015.1082994. Epub 2015 Sep 11.

PMID:
26360789
50.

Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.

Crawford ED, Moul JW, Sartor O, Shore ND.

Expert Opin Drug Metab Toxicol. 2015;11(9):1465-74. doi: 10.1517/17425255.2015.1073711. Review.

PMID:
26293510

Supplemental Content

Loading ...
Support Center